Gerson Nakazato

Dr. Gerson Nakazato

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
NDNelson Duran
Nelson Duran
MDMarcela Durán
Marcela Durán
MJMarcelo Bispo de Jesus
Marcelo Bispo de Jesus
Amedea B. SeabraAmedea B. Seabra
Amedea B. Seabra
WFWagner José Fávaro
Wagner José Fávaro
GNGerson Nakazato
Gerson Nakazato

11 June 2016 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
NDNelson Duran
Nelson Duran
GNGerson Nakazato
Gerson Nakazato
Amedea B. SeabraAmedea B. Seabra
Amedea B. Seabra

1 September 2016 in Biotechnology Advances
Verified
Journal Article
Closed access
NDNelson Duran
Nelson Duran
GJGiselle Z. Justo
Giselle Z. Justo
MDMarcela Durán
Marcela Durán
MBMarcelo Brocchi
Marcelo Brocchi
LCLivia Cordi
Livia Cordi
GNGerson Nakazato
Gerson Nakazato

1 February 2019 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
KBKarla Paiva Bocate
Karla Paiva Bocate
GRGuilherme Fonseca Reis
Guilherme Fonseca Reis
PSPatricia Canteri de Souza
Patricia Canteri de Souza
Admilton Gonçalves de OliveiraAdmilton Gonçalves de Oliveira
Admilton Gonçalves de Oliveira
NDNelson Durán
Nelson Durán
LPLuciano Aparecido Panagio
Luciano Aparecido Panagio

23 May 2016 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
SSSara Scandorieiro
Sara Scandorieiro
LCLarissa C. de Camargo
Larissa C. de Camargo
CLCesar A. C. Lancheros
Cesar A. C. Lancheros
SYSueli F. Yamada-Ogatta
Sueli F. Yamada-Ogatta
CNCelso V. Nakamura
Celso V. Nakamura
RKRenata Kobayashi
Renata Kobayashi
Bacterial resistance to conventional antibiotics has become a clinical and public health problem, making therapeutic decisions more challenging. Plant compounds and nanodrugs have been proposed as potential antimicrobial alternatives. Studies have shown that oregano (Origanum vulgare) essential oil (OEO) and silver nanoparticles have potent antibacterial activity, also against multidrug-resistant strains; however, the strong organoleptic characteristics of OEO and the development of resistance to these metal nanoparticles can limit their use. This study evaluated the antibacterial effect of a two-drug combination of biologically synthesized silver nanoparticles (bio-AgNP), produced by Fusarium oxysporum, and OEO against Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. OEO and bio-AgNP showed bactericidal effects against all seventeen strains tested, with minimal inhibitory concentrations (MIC) ranging from 0.298 to 1.193 mg/mL and 62.5 to 250 µM, respectively. Time-kill curves indicated that OEO acted rapidly (within 10 min), while the metallic nanoparticles took 4 h to kill Gram-negative bacteria and 24 h to kill Gram-positive bacteria. The combination of the two compounds resulted in a synergistic or additive effect, reducing their MIC values and reducing the time of action compared to bio-AgNP used alone, i.e., 20 min for Gram-negative bacteria and 7 h for Gram-positive bacteria. Scanning electron microscopy (SEM) revealed similar morphological alterations in Staphylococcus aureus (non-methicillin-resistant S. aureus, non-MRSA) cells exposed to three different treatments (OEO, bio-AgNP and combination of the two), which appeared cell surface blebbing. Individual and combined treatments showed reduction in cell density and decrease in exopolysaccharide matrix compared to untreated bacterial cells. It indicated that this composition have an antimicrobial activity against S. aureus by disrupting cells. Both compounds showed very low hemolytic activity, especially at MIC levels. This study describes for the first time the synergistic and additive interaction between OEO and bio-AgNP produced by F. oxysporum against multidrug-resistant bacteria, such as MRSA, and β-lactamase- and carbapenemase-producing Escherichia coli and Acinetobacter baumannii strains. These results indicated that this combination can be an alternative in the control of infections with few or no treatment options.

1 January 2014 in Industrial Crops and Products
Verified
Journal Article
Closed access
FDFlávia Debiagi
Flávia Debiagi
RKRenata K.T. Kobayashi
Renata K.T. Kobayashi
GNGerson Nakazato
Gerson Nakazato
LPLuciano A. Panagio
Luciano A. Panagio
SMSuzana Mali
Suzana Mali